Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol’s Baraclude Beats Hepsera In Two-year Trial

Apr 28 2008

• By Emily Hayes

Related Content

As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results

Apr 28 2009

Bristol-Myers Squibb’s Hepatitis B Therapy Baraclude Will Be Available April 8

Mar 30 2005

Baraclude Bests Hepsera On Viral Load Reduction In HBV Patients – Bristol Study

May 22 2007

Novartis/Idenix Tyzeka To Launch Within 30 Days For Treatment Of Hepatitis B

Oct 25 2006

Gilead Gets Positive Recommendation From EU Committee To Market Viread For Hepatitis B

Mar 20 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window